Radical cell therapy tested for Tough-to-Treat autoimmune conditions
NCT ID NCT07246096
Summary
This early-stage study is testing a new type of cell therapy called anti-CD19/BCMA universal CAR-T cells in people with severe autoimmune diseases that have not improved with standard treatments. The main goals are to check if the treatment is safe and to see if it can help control the diseases. The study will enroll 60 adults with conditions like lupus, rheumatoid arthritis, or scleroderma who have not responded to other therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Changhai Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.